Table 3.

Regression coefficients (B), 95% confidence intervals (CI), and p-values of multivariate regression analyses of hyperuricemia, hypertension, age, body mass index (BMI), serum creatinine, use of calcium channel blockers (CCB) and statins for platelet surface expression of activated glycoprotein (GP) IIb/IIIa in response to adenosine diphosphate (ADP), soluble CD40 ligand (sCD40L), light transmission aggregometry (LTA) in response to ADP, the VerifyNow P2Y12 assay, multiple electrode platelet aggregometry (MEA) in response to ADP, and the vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay in clopidogrel-treated patients (n = 301)

	Activated GPIIb/IIIa (MFI)			sCD40L (pg/mL)			LTA (maximal aggregation %)
	B	CI	p	B	CI	p	B	CI	p
Hyperuricemia	3.9	1.6–6.2	0.001	218.4	78.6–358.2	0.002	5.5	0.4–10.5	0.04
Hypertension	0.2	− 3.1–3.6	0.89	50.4	− 173.8–274.5	0.66	− 1.1	− 8.5–6.2	0.76
Age	0.1	0.05–0.2	0.003	0.2	− 5.6–5.9	0.96	0.3	0.1–0.5	0.001
BMI	0.3	0–0.5	0.05	− 15.6	− 30.8 to − 0.4	0.04	0.5	− 0.03–1.1	0.06
Creatinine	0.4	− 3.4–4.2	0.84	− 54.9	− 269–159.3	0.61	− 3.5	− 11.7–4.6	0.4
CCB	1.8	− 0.4–4	0.1	77.7	− 45.5–201	0.22	5.5	0.7–10.2	0.02
Statins	− 0.2	− 4.7–4.3	0.94	169.6	− 78.3–417.4	0.18	− 5	− 14.6–4.6	0.31
	VerifyNow P2Y12 assay (PRU)			MEA (AU)			VASP assay (PRI)
	B	CI	p	B	CI	p	B	CI	p
Hyperuricemia	22.3	− 0.6–45.2	0.06	5.9	0.2–11.5	0.04	7.2	1.1–13.3	0.02
Hypertension	− 24.1	− 57.3–9.2	0.16	− 1.5	− 9.7–6.7	0.72	− 12.5	− 21.9 to − 3	0.01
Age	3	2.2–3.9	< 0.001	− 0.2	− 0.4–0.05	0.12	0.01	− 0.2–0.3	0.91
BMI	2.7	0.2–5.2	0.03	0.5	− 0.1–1.1	0.1	1.3	0.7–2	< 0.001
Creatinine	14.8	− 22.1–51.6	0.43	− 10.2	− 19.4 to − 0.9	0.03	3.8	− 5.8–13.5	0.44
CCB	18.7	− 2.8–40.2	0.09	2.6	− 2.8–7.9	0.35	4.9	− 0.8–10.6	0.09
Statins	11.8	− 31.7–55.3	0.59	− 0.1	− 11.1–11	0.99	4.7	− 6.9–16.3	0.42

AU aggregation units, MFI mean fluorescence intensity, PRI platelet reactivity index, PRU P2Y12 reaction units